Teva Pharmaceutical Industries sank -7.2% this afternoon, compared to the S&P 500's day change of -0.0%. Today's losers may turn out to be tomorrow's winners, so be sure to check the stock's fundamentals before making an investment decision:
-
Teva Pharmaceutical Industries has logged a -4.0% 52 week change, compared to 16.8% for the S&P 500
-
TEVA has an average analyst rating of buy and is -33.44% away from its mean target price of $23.45 per share
-
Its trailing earnings per share (EPS) is $-0.15, which brings its trailing Price to Earnings (P/E) ratio to -104.1. The Health Care sector's average P/E ratio is 22.94
-
The company's forward earnings per share (EPS) is $2.77 and its forward P/E ratio is 5.6
-
The company has a Price to Book (P/B) ratio of 2.62 in contrast to the Health Care sector's average P/B ratio is 3.19
-
The current ratio is currently 1.0, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
The company's free cash flow for the last fiscal year was $749.0 Million and the average free cash flow growth rate is 11.7%
-
Teva Pharmaceutical Industries's revenues have an average growth rate of -0.3% with operating expenses growing at -0.4%. The company's current operating margins stand at -1.8%